Affymax Submits NDA For Peginesatide - RTT News PDF Print
RTT News
The EMERALD findings suggested that once-monthly peginesatide was similar to epoetin in maintaining hemoglobin levels in CRF patients on dialysis with anemia with a similar adverse event rate. The FDA is expected to decide in 60 days whether to file ...
Affymax files for approval of kidney disease drug Forbes
Affymax and Takeda Announce the Submission of a New Drug Application for

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.